An FDA panel prepares to vote on J & J's booster, just as a new study finds J & J recipients might be better off getting a booster from a different company.
An FDA panel prepares to vote on J & J's booster, just as a new study finds J & J recipients might be better off getting a booster from a different company.
It is much more acceptable in policy circles to talk about ways to make tax and transfer policy more progressive than ways to..